

Joel Picus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4329540/publications.pdf>

Version: 2024-02-01

40
papers

1,666
citations

516710

16
h-index

315739

38
g-index

43
all docs

43
docs citations

43
times ranked

2390
citing authors

#	ARTICLE	IF	CITATIONS
1	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 378-388.	10.7	327
2	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	2.8	280
3	Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. <i>Journal of Clinical Oncology</i> , 2011, 29, 1525-1530.	1.6	180
4	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. <i>European Urology</i> , 2018, 73, 847-855.	1.9	174
5	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1797-1806.	1.6	102
6	Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 829-836.	0.8	82
7	A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. <i>Cancer</i> , 2011, 117, 526-533.	4.1	70
8	SCATTER FACTOR-HEPATOCTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 165, 1325-1328.	0.4	56
9	A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 477-483.	1.9	54
10	Multidisciplinary treatment of biliary tract cancers. <i>Journal of Surgical Oncology</i> , 1994, 55, 239-245.	1.7	42
11	Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. <i>Molecular Imaging and Biology</i> , 2016, 18, 446-453.	2.6	40
12	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	1.6	26
13	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	3.7	22
14	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4624-4633.	7.0	21
15	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 680-713.	3.0	20
16	BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5018-5018.	1.6	15
17	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	7.0	14
18	A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradiation in resected pancreaticobiliary carcinoma. <i>Hpb</i> , 2015, 17, 587-593.	0.3	11

#	ARTICLE	IF	CITATIONS
19	Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).. Journal of Clinical Oncology, 2012, 30, 4118-4118.	1.6	11
20	A single-institution phase II trial of five fractions of radiotherapy followed by four courses of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 553-553.	1.6	9
21	Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 4540-4540.	1.6	8
22	Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. Journal of Clinical Oncology, 2018, 36, 582-582.	1.6	7
23	Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. PLoS ONE, 2014, 9, e107424.	2.5	6
24	Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study. Supportive Care in Cancer, 2016, 24, 2837-42.	2.2	6
25	Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. European Journal of Cancer, 2021, 154, 102-110.	2.8	6
26	Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Journal of Clinical Oncology, 2022, 40, 5081-5081.	1.6	6
27	Review: Brain Metastases in Bladder Cancer. Bladder Cancer, 2020, 6, 237-248.	0.4	4
28	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prosvac in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2021, 39, TPS192-TPS192.	1.6	4
29	Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC) Phase III.. Journal of Clinical Oncology, 2012, 30, 4571-4571.	1.6	4
30	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 64-72.	0.1	4
31	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prosvac in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, 5068-5068.	1.6	4
32	Advanced Prostate Cancer. American Journal of Cancer, 2002, 1, 13-22.	0.4	3
33	Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2012, 30, 3047-3047.	1.6	2
34	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate, 2022, 82, 1176-1185.	2.3	2
35	Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).. Journal of Clinical Oncology, 2012, 30, 259-259.	1.6	1
36	Advances in Management of Metastatic Colorectal Cancer. , 0, , 356-368.		0

#	ARTICLE	IF	CITATIONS
37	Association of survival and local radiotherapy to the bladder versus chemotherapy alone for patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2021, 39, 413-413.	1.6	0
38	Integrated clinicopathologic and molecular risk stratification for disease recurrence in muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 490-490.	1.6	0
39	Diagnosis and initial evaluation of patients with gastrointestinal stromal tumor (GIST): An observational study of 1,226 patients.. Journal of Clinical Oncology, 2012, 30, 10088-10088.	1.6	0
40	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2017, 35, 2553-2553.	1.6	0